New therapeutic strategies in HCV: Polymerase inhibitors

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 85-92

  Gerber, Ludmila ^a   Welzel, Tania M ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antiviral therapy; Hepatitis C; Non nucleoside polymerase inhibitors; Nucleoside polymerase inhibitors

Indexed keywords

ABT 072; ABT 333; ALIOS 2158; ALIOS 2200; BALAPIRAVIR; BI 207127; BILB 1941; BMS 986094; FILIBUVIR; GS 9669; IDX 375; LOMIBUVIR; MERICITABINE; MK 3281; NESBUVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5B; NUCLEOSIDE ANALOG; PEGINTERFERON; PLACEBO; PSI 938; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SETROBUVIR; SOFOSBUVIR; TEGOBUVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VCH 759; VCH 916; VX 759; VX 916;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE CYCLE; LIVER TOXICITY; LYMPHOCYTOPENIA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84872050504     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12068     Document Type: Review

References (36)

1. WHO. Hepatitis C: Available at http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index3.html. Accessed: August 2012.
2. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16: 75-90.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
4. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
5. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
6. Kim JL, Morgenstern KA, Dwyer MD, et al. Crystal structure of the hepatitis C virus (NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343-55.
7. Bressanelli S, Tomei L, Incitti I, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Nat Acad Sci 1996; 96: 13034-9.
8. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-63.
9. Lesburg CA, Cable MB, Ferrari E, et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937-43.
10. Biswal BK, Cherney MM, Wang M, et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem 2005; 280: 18202-10.
11. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-62.
12. de Bruijne J, de Rooij JV, van Vliet A, et al. Phase I study in healthy volunteers and patients with IDX-375, a novel non-nucleoside HCV polymerase inhibitor. Hepatology 2010; 52(Suppl): 1219A.
13. Jensen DM, Wedemeyer H, Herring RW, et al. High rates of early viral response, promising safety profile and lack resistance-related breakthrough in HCV GT1/4 patients treated with RG7128 plus pegIFN alfa-2a (40KD)/RBV: planned week 12 interim analysis from the PROPEL study. Hepatology 2010; 52(Suppl): 360-1A.
14. Pockros P, Jensen D, Tsai N, et al. SVR-12 among G1/4treatment-naïve patients receiving mericitabine in combination with peg-IFNa-2A7RBV: interim analysis from the JUMP-C study. J Hepatol 2012; 56(Suppl): 477-8.
15. Lawitz E, et al. PSI-7977 PROTON AND ELECTRON: 100% concordance of SVR4 with in HCV GT1, GT2, & GT3. J Hepatol 2012; 56(Suppl): S4.
16. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus peginterferon/ribavirin in a Phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV genotype 2/3. J Hepatol 2011; 54(Suppl): S28.
17. Gane EJ, et al. Once daily GS-7977 plus ribavirin in HCV genotypes 1-3: the ELECTRON. Hepatology 2012; 56(Suppl): 306-7A.
18. Hassanein T, Lawitz E, et al. Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naïve patients with HCV genotype 1, 4, and 6 infection in the ATOMIC study. Hepatology 2012; 56(Suppl): 307A.
19. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-75.
20. Gane EJ. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment naive HCV genotype 1 infected patients. J Hepatol 2012; 56(Suppl): 555-6.
21. Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naive Hepatitis C Patients: Available at http://investors.gilead.com/phoenix.zhtml?c = 69964&p=irol-newsArticle&ID=1684792&highlight. Accessed: October 2012.
22. Sulkowski M, et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/-ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. J Hepatol 2012; 56(Suppl): 560.
23. Erhardt A, Deterding K, Benhamou Y, et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther 2009; 14: 23-32.
24. Larrey D, Benhamou Y, Lohse AW, et al. Safety, pharmacokinetic and antiviral effect of BI207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol 2009; 50(Suppl): S383-4.
25. Brainard DM, Anderson MS, Petry A, et al. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281, in treatment-naive genotype 1a, 1b and 3 HCV-infected patients. Hepatology 2009; 50(Suppl): 1026-7A.
26. Cooper C, Lawitz EJ, Ghali P, et al. Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol 2009; 51: 39-46.
27. Lawitz E, Cooper C, Rodriguez-Torres M, et al. Safety, tolerability and antiviral activity of VCH-916, a novel non-nucleoside HCV polymerase inhibitor in patients with chronic HCV genotype 1 infection. J Hepatol 2009; 50(Suppl): S37.
28. Zeuzem S, Asselah T, Angus PW, et al. High SVR following IFN-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI 201335, polymerase inhibitor BI 207127 and ribavirin, followed by BI 201335 and PegIFN/ribavirin - the SOUND-C1 study. Hepatology 2011; 54(Suppl): 486-7A.
29. Nelson DR, Gane EJ, Jacobson IM, et al. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. Hepatology 2011; 54: 1435A.
30. Lawitz E, Rodriguez-Torres M, DeMicco M, et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol 2009; 50(Suppl): S384.
31. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55: 749-58.
32. Nelson DR, Lawitz E, Bain V, et al. High SVR12 with 16 weeks of tegobuvir and GS-9256 with peginterferon-alfa 2a and ribavirin in treatment-naive genotype 1 HCV patients. J Hepatol 2012; 56(Suppl): S6-7.
33. Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C: Available at http://investors.vrtx.com/releasedetail.cfm?releaseid=696581. Accessed: October 2012.
34. Zeuzem S, Soriano V, Asselah T, et al. Virologic response to an interferon-free regimen of BI 201335 and BI 207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the SOUND-C2 study. Hepatology 2011; 54(Suppl): 1436A.
35. Poordad F et al., A 12-week interferon-free regimen of ABT-450/r + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naïve HCV genotype-1-infected subjects and 47% of previous non-responders. J Hepatol 2012; 56(Suppl): S549-50.
36. Sulkowski M, Rodriguez-Torres M, Lawitz E, et al. Complete SVR4 rates in treatment-naïve HCV genotype 1a and 1b patients who achieved vRVR with an interferon-free all-oral regimen. Hepatology 2012; 56(Suppl): 298A.